Congruence of the current practices in *Hymenoptera* venom allergic patients in Poland with EAACI guidelines

Ewa Cichocka-Jarosz¹, Lavanya Diwakar², Piotr Brzyski¹, Beata Tobiasz-Adamczyk¹, Grzegorz Lis¹, Jacek J. Pietrzyk¹

**Abstract**

**Introduction:** Venom immunotherapy (VIT) practice is the definitive treatment for patients with potentially fatal allergic reactions to *Hymenoptera* stings. The aim is assessing compliance of VIT practice in Poland with the current European Academy of Allergy and Clinical Immunology (EAACI) guidance.

**Material and methods:** A multicentre study was carried out using a structured questionnaire which was sent by post to all VIT practitioners in Poland. Some questionnaire items were altered, in comparison to original version by adding additional answer options or allowing multiple answer option. The response rate was 100%. The obtained results were compared with the published EAACI guidelines.

**Results:** Twenty-six Polish centres took part in the survey. SSIgE and skin prick tests (SPT) are together used as the first line of investigation, whereas confirmatory intradermal tests (IDT) are applied in half of centres. Only a few centres measure baseline serum tryptase levels. The ultra-rush protocol is preferred. Antihistamine pre-medication is routinely practiced. A target dose equal to 100 µg is used in most centres. A 6-week interval between booster doses is the most frequent. Five years is considered as an optimal VIT duration. Before the VIT completion, SSIgE is evaluated in fifty percent of centres, whereas sting challenge is considered by half of responders.

**Conclusions:** There are some differences between current practice in Poland and the EAACI recommendations, indicating areas requiring better compliance. Comparison between Poland and the United Kingdom revealed that health service organization and health care funding may play a major role in the provision of allergy services. This may affect the extent to which international guidance may be applied in individual countries. It is worth considering conducting the same survey in other European countries.

**Key words:** current practice, serum-specific IgE, skin tests, venom immunotherapy.

**Introduction**

European Academy of Allergy and Clinical Immunology (EAACI) recommendations summarize the results of studies evaluating the efficacy
and safety of venom allergy diagnosis and management [1, 2] (Table I). The adoption of these recommendations is dependent upon education, health system organization and cultural aspects unique to the country. Allergy to insect venom is a serious, potentially life-threatening condition. Venom immunotherapy (VIT) is the only treatment that has proven effective at decreasing the incidence and seriousness of subsequent sting reactions in affected individuals [1, 2]. Accordingly, patients who have experienced a systemic reaction to insect sting should be referred to an allergist-immunologist for diagnosis. The VIT is obligatorily indicated in patients with a history of a life-threatening (cardiac or respiratory – grade 3 and 4 according to Mueller’s classification) systemic reaction to Hymenoptera stings and demonstrable serum-specific IgE (SSIgE) antibodies to Hymenoptera venom [1-3]. In the case of IgE-mediated grade 2 and grade 1 reaction, additional risk factors such as high exposure, or decreased quality of life arising from anxiety, are taken into consideration while establishing the indications for VIT [2, 4]. There are some differences between the European and US approach to venom allergic patients. In the US, VIT introduction is more common in mild skin reactions, and trials of treatment in large local reactions are becoming increasingly popular [5]. Guidelines are of increasing importance in clinical practice. If corresponding recommendations are not followed, the quality of medical care will suffer. Ignoring recommendations from guidelines may also have legal consequences. Therefore the gap that exists between both national and international recommendations and clinical practice must be taken seriously. There are also Polish national guidelines concerning management of venom allergic patients, which strictly follow EAACI recommendations according to points from 2 to 6 and points from 18 to 24 presented in Table I, and do not refer to the other ones [6]. The first comprehensive audit of current practices in management of Hymenoptera venom allergic patients among the European Union countries was done in the United Kingdom [7].

The aim of our study was to estimate what level of congruence with EAACI guidelines is presented by current practice in management of Hymenoptera venom allergic patients in Poland.

### Material and methods

In Poland, diagnostic investigation and management of venom allergic patients are exclusively conducted in 26 (18 for adults, 8 for children) university or large public health centres. A list of these centres is available on the Polish Allergology Society website (www.pta.pl). A previously published questionnaire was translated from

| **No** | **Topic** |
|--------|-----------|
| 2. | First line of investigation: |
| 3. | SPT |
| 4. | RAST |
| 5. | Highest venom concentration used in SPT [µg/ml]: |
| 6. | 100 |
| 7. | IDT confirmatory in diagnosis |
| 8. | Highest venom concentration used in IDT [µg/ml]: |
| 9. | 10 |
| 10. | Treatment strategy in case of severe reaction and uncertain culprit insect: |
| 11. | Both venoms |
| 12. | Discharge with Epipen |
| 13. | Baseline plasma tryptase in patients with history of severe SR |
| 14. | Discharge with Epipen |
| 15. | Follow up in 3 months |
| 16. | Strategy in systemic reaction with non-detectable venom sIgE and normal baseline serum tryptase: |
| 17. | Discharge with Epipen |
| 18. | Follow up in 3 months |
| 19. | Antihistamines in premedication of VIT: |
| 20. | Troublesome local reactions |
| 21. | Grade 2-4 in Mueller’s scale side effects during VIT: |
| 22. | Accelerated regimen |
| 23. | Maximum time interval between the maintenance doses [weeks]: |
| 24. | 4 within first year of treatment |
| 25. | 6 within 2-5 years of treatment |
| 26. | 8 over 5 years of treatment |
| 27. | Routine target maintenance dose [µg/ml]: |
| 28. | 100 |
| 29. | IgG4 evaluation during or at the end of VIT: |
| 30. | Not advisable |
| 31. | Optimal VIT duration [years]: |
| 32. | 3-5 |
| 33. | Sting challenge considered at the end of VIT: |
| 34. | Advisable |
| 35. | sIgE evaluation at the end of VIT: |
| 36. | Advisable |
| 37. | Specific IgE detectable at the end of 3-5 years VIT period as indicator for VIT prolongation: |
| 38. | Advisable |
| 39. | In grade 4 reactions only |

*Number in left column refers to number of item in the questionnaire.
English into Polish [6]. The translation process was done independently by two Polish native speakers with professional skills in English. Differences between the two versions were identified and eliminated during a consensus meeting. Then the questionnaire was retranslated and compared to the original version. Some adaptations, reflecting local differences in VIT practice, were required in the Polish version of the questionnaire as follows: A) question 2, the choice of both methods (RAST and SPT) performed simultaneously as a first line of investigation was allowed; B) questions 3 and 12, the choice of other SPT extracts/treatment extracts, respectively, was added; C) questions 10, 11, 13 and 16, due to characteristics of VIT practices in Poland, were treated as multiple answer questions as opposed to multiple choice ones in the UK; D) question 14, information about previous experience with the accelerated protocol was reported as separated options; E) question 24, the answer option “other” was added. The questionnaire was sent to all centres by post. Answers were obtained from senior doctors directly responsible for management of venom allergic patients. The congruence of current practice with EAACI recommendations was expressed as the percentage of centres strictly following the recommended procedures.

Results

The audit response rate was 100% (in a few cases, a reminder by phone was necessary).

Diagnostic tests

As the first line of investigation, almost two thirds of Polish centres performed skin prick tests (SPT) with concentration 100 µg/ml. Serum-specific IgE (SSIgE) application was common. Intradermal tests (IDT) with venom concentration equal to 1.0 µg/ml as a confirmatory procedure were performed in over one half of Polish centres.

VIT PROTOCOL (including dosage, antihistamines, duration)

The most common protocol of VIT incremental dose in Poland was ultra rush. Almost all the centres used the maintenance dose equal to 100 µg. One half of the centres practised a 6-week interval between the maintenance doses. Three to five years was the most frequent VIT duration, despite the severity of past sting reaction. In Polish practice, almost three fourths of the centres used premedication with antihistamines in all the treated patients. One third of the centres performed acceleration of the schedule and increasing the maintenance dose from 100 µg to 200 µg in case of grade 2-4 side effects during VIT.

Management of non-evident cases

Thirty-five percent of centres respected the strategy of providing self-injectable epinephrine upon discharge and performing follow-up in 6-12 months in a patient with SR, non-detectable SSIgE and normal baseline serum tryptase, while the same strategy was employed by only 27% of centres in patients with the same history and negative sIgE, but elevated baseline serum tryptase.

Additional tests (tryptase, IgG4, SSIgE before stopping therapy, sting challenge)

Baseline serum tryptase at the beginning of treatment only in case of severe systemic reactions was performed in 40% of the centres where the estimation of this marker is available, which constitutes less than 20% of centres in Poland. At the end of VIT, almost one half of centres evaluated SSIgE; similarly, almost one half of them considered sting challenge. Specific IgG4 level both before treatment and before stopping VIT was rarely practised.

Discussion

The results obtained in this questionnaire survey allowed for description of current practice in management of the whole population of insect venom allergic patients (both adults and children) in Poland. We realize that the option of a self-completed questionnaire-based study limits the validity of obtained results. However, for objectivity of the data, answers to the questions were exclusively obtained from senior doctors directly responsible for management of venom allergic patients. They were all informed about the research purpose of the survey. On the other hand, we followed the same way of data collecting as in a British study, so comparisons to those data could be performed [7]. Previously only preliminary results of a multicentre (8 centres) study dedicated to current practices in Poland in management of venom allergic children were published [8]. The EAACI recommendations are strictly the same for adults and children, so only showing the current practices in all Polish allergy centres will reflect how the Polish health system allows for congruence of the current practices with the guidelines. It also indicates the topics which should be urgently improved. The total analysis is additionally justified, as centres for children closely cooperate with centres for adults, transferring patients at the age over 18 years for continuation of treatment. Finally, total results will be more representative for Poland against the European background, allowing them to be compared with British study results [7]. It may also encourage
authors from other European countries to conduct similar studies, enabling further comparison (a panEuropean view).

Comparison of current practice in Poland with EAACI recommendations

There are some discrepancies between the current practice in Poland and the EAACI recommendations [1, 2]. The results of our study are shown in Table II.

Diagnostic tests

Using both tests (SPT and SSiGE) together as the first line of investigation in Poland expresses their good availability and allows diagnostic duration to be shortened. It should be strongly emphasized that venom skin testing requires highly experienced staff to achieve highly repeatable results [9]. In patients with a negative SPT, it is therefore recommended to confirm this result in IDT. Positive results of IDT with venom concentration of 1 µg/ml confirm venom sensitization, while negative results exclude it. For this reason, some centres do not perform SPT. In our experience, positive results of SPT in children occur very seldom. A high percentage of centres evaluating SSiGE express good accessibility of the test, though its sensitivity is somewhat lower than that of IDT [10]. For providing the highest available sensitivity, the newer, third generation methods (ImmunoCAP, Immulite) are the most recommended [11, 12]. Both are in use in Poland. A “negative” result of skin testing could be due to insufficient sensitivity of tests or too long interval from the sting-induced reaction [12]. In patients with a history of severe SR reaction, confirmation of IgE-mediated reaction is important and allows for VIT commencement as a treatment of choice.

VIT protocol

The maintenance dose equal to 100 µg was almost fully respected in Poland. Different schedules of treatment concerning the up-dosing phase required to reach the maintenance dose may last several weeks to months (conventional, clustered), a few days or even hours (rush or ultra rush protocol, respectively) [2, 13]. The accelerated protocols predominate in Poland. The most popular aqueous venom extracts in Poland are Venomenhal (HALAllergy) and PharmaGen (ALKAbello). Only a few centres use depot venom extract Alutard (ALKAbello). A 4-week interval between maintenance doses during the first year, 6 weeks within 2-5 years and 8 weeks over 5 years of VIT are recommended [2], though in the case of depot extracts, the interval from the beginning of maintenance doses might be up to 8 weeks. In the case of grade 2-4 side effects during VIT, a high percentage of Polish centres accelerate the schedule and increase the maintenance dose from 100 µg to 200 µg. In-patient management of these cases makes this procedure possible in Poland. According to our clinical observations, VIT-treated children well tolerating venom doses are protected at the early stage of treatment, which is consistent with the other data [14]. In Poland, pre-treatment with antihistamines was applied to all patients, probably as a result of well-known data of Polish origin on their advantageous effect on the immune response during VIT [15-17]. More clinical data supporting the use of antihistamine pre-treatment in all VIT patients are needed.

In the case of managing a patient with an unclear background of systemic reaction to sting, the original British questionnaire-reported time of a follow-up examination after 6-12 months is not in line with the EAACI recommendation of a follow-up visit 3 months after the event.

Non-evident cases

The important topic of safety indicates the low number of Polish centres providing self-injectable epinephrine upon discharge to patients after SR, with non-detectable SSiGE and uncertain insect stinging, normal or elevated baseline serum tryptase. It is a matter of question whether the emergency department (ED) staff supplies these patients with emergency kits immediately after severe SR, before referring them to a specialist [2], which is strongly recommended [18-20]. Epipen, Anapen and Fastject are well-known self-injectable epinephrine specimens. Additionally, a low-cost product of Polish origin is also available on the market. Findings that only about one-third of patients received a prescription for self-injectable epinephrine indicate an urgent need for education [20, 21]. Also, providing self-injectable epinephrine immediately after reaction (ED) is recommended in the case of patients with SR and both honeybee and wasp venom positivity or an uncertain culprit insect. True double positivity to venoms creates a problem in the selection of venom for immunotherapy. True double positivity should be distinguished from the presence of cross reacting carbohydrate determinants of venoms [22]. When true double sensitivity has been confirmed, application of VIT with both venoms by a specialist is recommended. In the case of patients with a history of SR and undetectable IgE and normal baseline tryptase, follow-up within 3 months is recommended. It is justified in the case of severe SR, as negative skin tests after a recent sting anaphylaxis can occur during the refractory period of “anergy” for the first weeks after the event [1, 23].
### Table II. Characteristics of current diagnostic and therapeutic practice in patients with Hymenoptera venom allergy in Poland based on questionnaire study

| No | Question                                                                 | n (%)                                    |
|----|--------------------------------------------------------------------------|------------------------------------------|
| 2. | First line of investigation:                                             |                                          |
|    | SPT                        | 0 (0)                                   |
|    | RAST                       | 8 (31)                                  |
|    | SPT + RAST                 | 18 (69)                                 |
| 3. | Skin prick extract manufacturer:                                        |                                          |
|    | ALK Pharmalgen              | 4 (15)                                  |
|    | ALK commercial skin testing extract                                    | 0 (0)                                   |
|    | HalAllergy                  | 15 (58)                                 |
|    | Venomil                     | 1 (4)                                   |
|    | Alutard ALK                 | 1 (4)                                   |
|    | ALK + HalAllergy            | 5 (19)                                  |
|    | Other                       | 0 (0)                                   |
| 4. | Highest venom concentration used in SPT [µg/ml]:                         |                                          |
|    | 10                         | 2 (8)                                   |
|    | 100                        | 22 (84)                                 |
|    | 200                        | 2 (8)                                   |
|    | 300                        | 0 (0)                                   |
| 5. | IDT confirmatory in diagnosis                                           | 23 (88)                                 |
| 6. | Highest venom concentration used in IDT [µg/ml]:                         |                                          |
|    | 0.01                       | 2 (8)                                   |
|    | 0.1                        | 5 (19)                                  |
|    | 10                         | 18 (69)                                 |
|    | 10                         | 1 (4)                                   |
| 7. | Treatment strategy in case of severe reaction and uncertain culprit insect: |                                          |
|    | Both venoms                 | 7 (27)                                  |
|    | Venom of higher IgE level                                             | 7 (27)                                  |
|    | Discharge with Epipen       | 1 (4)                                   |
|    | Other                      | 11 (42)                                 |
| 8. | Baseline plasma tryptase in patients with history of SR                 | 10 (39)                                 |
| 9. | Check tryptase in:                                                     |                                          |
|    | Systemic severe reaction                                             | 4 (40%)                                 |
|    | All systemic reactions, irrespectively of their severity               | 6 (60%)                                 |
| 10. | Strategy in systemic reaction with non-detectable venom sIgE and normal baseline serum tryptase²: |                                          |
|    | Discharge with advice       | 6 (23)                                  |
|    | Discharge with Epipen       | 15 (58)                                 |
|    | Follow up in 6-12 months    | 20 (77)                                 |
|    | Commence immunotherapy     | 0 (0)                                   |
| 11. | Strategy in systemic reaction with non-detectable venom sIgE, elevated baseline serum tryptase²: |                                          |
|    | Discharge with advice       | 0 (0)                                   |
|    | Discharge with Epipen       | 11 (42)                                 |
|    | Follow up in 6-12 months    | 18 (69)                                 |
|    | Commence immunotherapy     | 1 (4)                                   |
| 12. | Immunotherapy extract manufacturer:                                    |                                          |
|    | ALK (Pharmalgen/Alutard)    | 5 (19)                                  |
|    | HALAllergy                  | 11 (42)                                 |
|    | Both                       | 6 (24)                                  |
|    | Other                      | 4 (15)                                  |
| 13. | VIT protocol commonly applied:                                         |                                          |
|    | Conventional               | 4 (15)                                  |
|    | Clustered                  | 6 (23)                                  |
|    | Rush                       | 5 (19)                                  |
|    | Ultra rush                 | 15 (58)                                 |
| 14. | Accelerated protocols ever applied:                                    |                                          |
|    | Rush                       | 14 (54)                                 |
|    | Ultra rush                 | 16 (62)                                 |
| 15. | Antihistamines in premedication of VIT:                                 |                                          |
|    | Troublesome local reactions  | 12 (46)                                 |
|    | Systemic reactions          | 7 (27)                                  |
|    | Asthma or cardiorespiratory problems                                 | 2 (8)                                   |
|    | All patients                | 19 (73)                                 |
|    | Other                      | 0 (0)                                   |
| 16. | Grade 2-4 in Mueller’s scale side effects during VIT:                   |                                          |
|    | Discontinue treatment       | 3 (12)                                  |
|    | Accelerated regimen         | 8 (31)                                  |
|    | Persist with VIT as usual   | 2 (8)                                   |
|    | Other                      | 13 (50)                                 |
| 17. | Maximum time interval between maintenance doses [weeks]:                |                                          |
|    | 4                          | 2 (8)                                   |
|    | 6                          | 13 (50)                                 |
|    | 8                          | 2 (8)                                   |
|    | ≥12                        | 0 (0)                                   |
|    | Other                      | 9 (34)                                  |
| 18. | Routine target maintenance dose [µg/ml]:                                |                                          |
|    | 100                        | 24 (92)                                 |
|    | 150                        | 0 (0)                                   |
|    | 200                        | 2 (8)                                   |
Management of venom allergic patients in Poland

Table II, cont.

| No | Question                                                                 | n  | (%) |
|----|---------------------------------------------------------------------------|----|-----|
| 20 | IgG4 evaluation during or at the end of VIT:                              | 2  | 8   |
| 21 | Optimal VIT duration [years]:                                            |    |     |
|    | 2                                                                        | 0  | 0   |
|    | 3                                                                        | 1  | 4   |
|    | 5                                                                        | 19 | 73  |
|    | > 5                                                                      | 15 | 4   |
|    | Other                                                                    | 2  | 8   |
| 22 | Sting challenge considered at the end of VIT:                            | 12 | 46  |

*Answer options altered in comparison to the original version, n – number of centres which reported chosen category.

Additional tests

Baseline serum tryptase level expresses the whole body mast cell load and is a predictor of severe SR [24, 25]. It is recommended to be determined in all patients with such a history, though the frequency of its clinical application is still too low [1, 21]. In treated patients, VIT leads to a variety of specific immunological changes still being determined. It is unknown, however, which parameter shifts might indicate therapeutic success [26, 27]. The level of specific IgG4 primarily reflects exposure, and is not recommended in routine assessment [28]. Provocation with sting challenge is indicated in individual patients on a maintenance dose of VIT to identify those who are not yet protected [29, 30]. Sting challenge before the end of VIT was considered in Poland, though formulation “considered” should not be understood as equal to “performed”.

The results of specific IgE in monitoring the end of treatment often influenced the decision of VIT prolongation in Poland. The sSIgE evaluation at the end of VIT, though widely used in Poland, is helpful for making the decision on VIT cessation in the case of both skin and sSIgE negative results. Otherwise, the decision should be made individually. The VIT prolongation is justified in the case of a life-threatening reaction in the past and sSIgE still detectable at the end of 3-5 years of treatment, which is a rather common practice in Poland.

Comparison of current practice between Poland and the United Kingdom

Since almost the same questionnaire was used in both Poland and the United Kingdom, we were able to make a comparison of VIT practice between these two regions.
respected in different countries to the same extent. It would be interesting to compare data from other European countries and, in the case of insufficient acceptance of guidelines, to analyse the reasons. Potential explanations are increasing economic pressure, insufficient medical education, poor patient compliance and the possibility that recommendations of guidelines cannot be implemented for practical reasons. The results might be a basis for a study of new guidelines and helpful in improvement of educational programmes. As it is a matter of safety and legal consequences, it is important to achieve a pan-European consensus to obtain EAACI guidance and on how EAACI could probably do more to ensure homogeneity in this respect in Europe. Similarly, as in the other health promotion initiatives, in all settings it must be scientifically sound, culturally acceptable, and managerially feasible. Evidence by itself is not enough to generate action. Leadership is essential, this being “the capacity to influence others to work together to achieve a common purpose” [32, 33].

Acknowledgments

We declare no financial relationship with biotechnology/pharmaceutical manufacturers mentioned in this manuscript.

References

1. Bilo BM, Rueff F, Mosbech H, Bonifazi F, Oude-Elberink JN; Panel of Experts of EAACI Interest Group on Insect Venom Hypersensitivity. Diagnosis of Hymenoptera venom allergy. Allergy 2005; 60: 1339-49.
2. Bonifazi F, Jutel M, Bilo BM, Birnbaum J, Müller U; Panel of Experts of EAACI Interest Group on Insect Venom Hypersensitivity. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005; 60: 1459.
3. Moffitt JE, Golden DBK, Reisman RE, et al. Stinging insect hypersensitivity: a practice parameter update. J Allergy Clin Immunol 2004; 114: 869-86.
4. Oude-Elberink JNG, de Monchy JGR, van der Heide S, Oude-Elberink JN; Panel of Experts of EAACI Interest Group on Insect Venom Hypersensitivity: Prevention and efficacy of immunotherapy in the paediatric population. Allergol Immunopathol 2009; 37: 111-5.
5. Jutel M, Watanabe T, Klunker S, et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 2001; 413: 420-5.
6. Müller U, Hari I, Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol 2001; 107: 81-6.
7. Reimers A, Hari Y, Müller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy 2000; 55: 484-8.
8. Tse Y, Ryland G. Emergency management of anaphylaxis in children and young people: new guidance from the Resuscitation Council (UK). Arch Dis Child Epid Pract 2009; 94: 97-101.
9. Moraro A, Roberts G, Clark A, et al. EAACI Task Force on Anaphylaxis in Children. The management of anaphylaxis in childhood. Allergy 2007; 62: 857-71.
10. Simons FER, Frew AJ, Ansoltegui I, et al. Risk assessment anaphylaxis current and future approaches. J Allergy Clin Immunol 2007; 120: 2-24.
11. Simons FER. Anaphylaxis: recent advances in assessment and treatment. J Allergy Clin Immunol 2009; 124: 625-36.
12. Müller UR, Johansen N, Petersen AB, Fromberg-Nielsen J, Haeberli G. Hymenoptera venom allergy: analysis of double positivity to honey bee and Vespula venom by estimation of IgE antibodies to species-specific major allergens Api m 1 and Ves v 5. Allergy 2009; 64: 543-8.
13. Przybilla B, Ruöff F. Hymenoptera venom allergy. J Dtsch Dermatol Ges 2010; 8: 114-27.
14. Ruöff F, Przybilla B, Müller U, Mosbech H. The sting challenge test in hymenoptera venom allergy. Position paper of the Subcommittee on insect venom allergy of the European Academy of Allergology and Clinical Immunology. Allergy 1996; 51: 216-25.
15. Kucharewicz I, Bodzenta-Lukaszky A, Szynanski W, Mroczko B, Szmitkowski N. Basal serum tryptase level correlates with severity of hymenoptera sting and age. J Investig Allergol Clin Immunol 2007; 17: 65-9.
16. Brasch J, Maudisch T. Immunotherapy with wasp venom is accompanied by wide-ranging immune responses that need further exploration. Acta Derm Venerol 2009; 89: 466-9.
17. Pereira-Santos MC, Babtista AP, Melo A, et al. Expansion of circulating foxp3+CD25brightCD4+ T cells during specific venom immunotherapy. Clin Exp Allergy 2007; 38: 291-7.
18. Ewan PW, Deighton J, Wilson AB, Lachman PJ. Venom-specific IgG antibodies in bee and wasp allergy: lack of
correlation with protection from stings. Clin Exp Allergy 1993; 23: 647-60.
29. Ruëff F, Przybilla B, Biló MB, et al. Predictors of severe systemic anaphylactic reactions to patients with hymenoptera venom allergy: importance of baseline serum tryptase – a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124: 1047-54.
30. Reisman RE. Duration of venom immunotherapy: relationship to the severity of symptoms of initial insect sting anaphylaxis. J Allergy Clin Immunol 1993; 92: 831-6.
31. Haugaart L, Nooregaard OFH, Dahl R. In-hospital sting challenges insect venom-allergic patients sting challenges in insect venom-allergic patients after stopping venom immunotherapy. J Allergy Clin Immunol 1991; 87: 699-702.
32. White F, Nanan D. Community health case studies selected from developing and developed countries – common principles for moving from evidence to action Arch Med Sci 2008; 4: 358-63
33. Gasparyan AY, Banach M. A medium science communication in our times. Arch Med Sci 2009; 5: 1.